Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA
FDA Confirms Vitaros Regulatory Pathway
Company Seeking Partner to Develop Vitaros in U.S.
Company Evaluating Strategic Alternatives
SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the outcome of its end-of-review meeting with the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Vitaros(TM) (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction.
The preliminary end-of-review meeting minutes support a plan to address issues cited by the FDA in its February 15, 2018 Complete Response Letter (CRL) for the Vitaros NDA. Specifically, the FDA confirmed during the meeting that the company should develop a new Vitaros formulation that reduces the concentration of DDAIP.HCl from 2.5% to 0.5% in order to address the tumor promotion and partner transference safety concerns noted in the CRL. The FDA also confirmed that two new Phase 3 clinical efficacy trials with the reformulated product should be conducted prior to resubmitting the NDA and that the trials should include an assessment of the potential risk of enhanced sexually transmitted infections with the new formulation. In addition, the FDA requested certain pharmacokinetic assessments that we expect can be completed as part of the requested Phase 3 program and any additional clinical or commercial safety data generated prior to a resubmission. Lastly, the FDA stated that the Chemistry, Manufacturing and Control (CMC) section in the resubmission will need to be updated with data generated during development of the new formulation.
The FDA previously issued a CRL for the Vitaros NDA, indicating that it could not approve the NDA for Vitaros in its present form, identifying deficiencies related to CMC and whether the modest treatment effect of Vitaros outweighed certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation.
"While we are pleased that the FDA has outlined a clear regulatory pathway for Vitaros, which we believe provides a path to approval in the U.S., the cost and timeline associated with a reformulation effort and completing additional phase 3 clinical trials exceeds our current resources and our ability to raise additional capital. Therefore, we have initiated discussions with interested parties for the U.S. Vitaros rights to enable its continued development and potential approval in exchange for financial terms commensurate with a development stage asset. In parallel, the Board of Directors has determined that Apricus should evaluate strategic alternatives or other business combinations, with the goal of maximizing shareholder value," said Richard Pascoe, Chief Executive Officer.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates: Vitaros, a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan); and RayVa, a product candidate which has completed a Phase 2a clinical trial for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros(TM) is Apricus' trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States. RayVa(TM) is Apricus' trademark, which is registered in certain countries throughout the world and pending registration in the United States.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: the potential to enter into a U.S. partnership regarding Vitaros; Apricus' ability to identify and conclude strategic transactions or other business combinations; and the timing of any clinical and non-clinical trials and studies to address the FDA's concerns and whether the results of such trials and studies would be sufficient to overcome the deficiencies raised in the CRL. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside of Apricus' control, including, but not limited to: Apricus' financial position and need for additional capital to fund its operations, which may be adversely impacted if Apricus is unable to maintain the continued listing of its common stock on the Nasdaq stock market; a partnership with respect to U.S. Vitaros and any larger strategic transaction or other business combination may not be available on acceptable terms or at all; Apricus' ability to address any conditions for approvability of Vitaros raised by the FDA in the CRL; the risks of any additional adverse safety or other data arising from the sales and use of Vitaros in certain countries in Europe and elsewhere; competition in the ED market; and other risks identified by Apricus in its reports filed with the Securities and Exchange Commission (SEC). These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus' most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from Apricus.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
GlobeNewswire Test Release14.7.2018 07:00 | Pressemelding
LOS ANGELES, July 13, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Senior Director, Global Head of GlobeNewswire Media Relations Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or David Didier Lislet Manager, GlobeNewswire Media Relations, EMEA Phone: +33 185 341 347 Mobile: +33 603 702 885
Brookfield Asset Management 2018 Second Quarter Results Conference Call And Webcast13.7.2018 16:04 | Pressemelding
Date: Thursday, August 9, 2018 Time: 11:00 a.m. (Eastern Time) TORONTO, July 13, 2018 (GLOBE NEWSWIRE) -- Second Quarter Conference Call You are invited to participate in Brookfield Asset Management's 2018 Second Quarter Conference Call & Webcast on Thursday, August 9, 2018 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on August 9th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com "News - Press Releases." The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial (877) 255-3077 toll free in North America, or for overseas calls please dial (647) 252-4453 at approximately 10:50 a.m. The Conference Call will also be Webcast live at https://event.on24.com/wcc/r/1795914/64490BD29FBE43FAF176E3AF02943920. For those unable to p
Squirrels Research Labs Announces Acorn Cryptocurrency Acceleration Hardware12.7.2018 21:04 | Pressemelding
NORTH CANTON, Ohio, July 12, 2018 (GLOBE NEWSWIRE) -- Squirrels Research Labs today announced Acorn, a new hardware component that improves efficiency and effectiveness of cryptocurrency mining. "We developed a piece of hardware called Acorn that increases the effectiveness of existing GPU mining operations without adding a significant cost," Squirrels president David Stanfill said. "This is a brand new concept that's never been done before." Acorn works in sync with GPUs to offload work that typically creates bottlenecks in mining. It performs the work much faster, resulting in an increase in overall mining efficiency. Initially three models will be available: CLE-101, CLE-215 and CLE-215+. Each model uses high-performance FPGA chips from Xilinx Inc. (NASDAQ:XLNX) in an M.2 slot to perform the least GPU-efficient parts of cryptocurrency mining. All Acorn models work with memory-intensive algorithms like Ethash and CryptoNight V1. The 215 and 215+ models work with both memory-intensive
NRT & Sightline Secure Multi-Year Exclusive Agreement with Ocean Resort Casino12.7.2018 19:30 | Pressemelding
Atlantic City's newest resort casino opens with a seamless customer experience for omni-channel solutions LAS VEGAS, July 12, 2018 (GLOBE NEWSWIRE) -- NRT Technology Corp. and Sightline Payments, LLC (together "NRT Sightline") today announced that Ocean Resort Casino in Atlantic City, N.J. opened its doors with the full suite of NRT Sightline solutions, including Play+, QJ self-serve kiosks, Cash+ ATM, credit and debit advances, VisuaLimits table signs and analytics, and the full suite of NCC credit and compliance solutions. "NRT Sightline has invested in cutting-edge technology that gives us a competitive advantage, and we look forward to our long-term partnership with this world-class technology leader," said Alan Greenstein, Chief Financial Officer of Ocean Resort Casino. "Ocean Resort Casino is Atlantic City's showcase property for a truly omni-channel guest experience. As the lines that separate cash and cashless commerce converge in gaming, our solutions remove friction from the
VeriTransfer(TM) Unveils the First Known Proof-of-Concept for a Blockchain Enabled Firearms Licence Verification and Ownership Transfer12.7.2018 17:43 | Pressemelding
Blockchain Enabled Firearms Solution Ensures Instant Verification of Ownership and Safe Transfer While Maintaining Data Privacy TORONTO, July 12, 2018 (GLOBE NEWSWIRE) -- VeriTransfer(TM) today announced the completion of its Proof-of-Concept ("POC") of the first publicly announced Blockchain enabled solution that decentralizes the process of storing the ownership rights and transfer of firearms. VeriTransfer(TM) is also pleased to announce that it will donate a percentage of all future revenues or the proceeds from any future sale of the company towards foundations whose mission is to end gun violence and build safer communities. The Gun Epidemic & The Economic Impact The United States hosts 4.4% of the world's population, but almost 50% of the 644 million civilian-owned guns globally are located in the U.S. Disturbingly, more American citizens have died as a result of gunshots in the U.S. since 1968 than on the battlefield of all the wars in American history from 1175 to 2015. In add
PhosAgro and Growthpoint Properties Among Big Winners on Institutional Investor's Inaugural Emerging EMEA Executive Team Ranking12.7.2018 16:32 | Pressemelding
NEW YORK, July 12, 2018 (GLOBE NEWSWIRE) -- PhosAgro and Growthpoint Properties are among several notable firms that took home leading positions across their respective sectors in Institutional Investor's inaugural ranking of the region's best chief executives, top CFOs, investor relations professionals, and investor relations companies. More than 500 buy-side analysts, asset managers, and sell-side researchers at nearly 300 firms, managing an estimated $272 billion in equities in Emerging EMEA named the best chief executives, top CFOs, investor relations professionals, and investor relations companies across 12 business sectors. Buy-side analysts, money managers and sell-side researchers at securities firms and financial institutions that cover the region identified up to four companies that excel in up to ten investor relations attributes including: Senior executives are accessible IR team is well informed and empowered to speak authoritatively on the company's behalf Timely and appr
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom